Abstract | BACKGROUND: METHODS: This study retrospectively analyzed the clinical data of 49 patients with advanced NSCLC and high PD-L1 expression. Immunohistochemistry was performed with 22C3 antibody, and the expression level of PD-L1 was evaluated according to tumor proportion score (TPS). Objective response rate (ORR) and progression free survival (PFS) were compared by groups of different clinical characteristics. RESULTS: ORR of monotherapy and combination therapy group was 47.1% (8/17) and 43.8% (14/32), respectively, without statistical difference (P=0.825). The median PFS of monotherapy and combination therapy group was 8.0 months and 6.8 months, respectively, without statistical difference (P=0.502). Statistical analysis of predictors of immunotherapy for the patients showed first-line immunotherapy had better ORR than subsequent immunotherapy (12/19, 63.2% vs 10/30, 33.3%, P=0.041), however no difference in PFS. And there were no differences in ORR or PFS among groups of age, gender, smoking status, performance status (PS), pathological type, tumor size and tumor-node- metastasis (TNM) stage. CONCLUSIONS: The therapeutic effect is similar between ICIs monotherapy and combination chemotherapy for patients with advanced NSCLC and high PD-L1 expression. ORR of first-line immunotherapy was better in patients with advanced NSCLC and high PD-L1 expression. The optimal treatment for this population remains further prospective clinical studies.
|
Authors | Haoyang Li, Na Qin, Mengjun Yu, Li Ma, Yuhua Wu, Hui Zhang, Xinyong Zhang, Xi Li, Jinghui Wang |
Journal | Zhongguo fei ai za zhi = Chinese journal of lung cancer
(Zhongguo Fei Ai Za Zhi)
Vol. 24
Issue 3
Pg. 161-166
(Mar 20 2021)
ISSN: 1999-6187 [Electronic] China |
PMID | 33819965
(Publication Type: Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- B7-H1 Antigen
- Immune Checkpoint Inhibitors
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
(administration & dosage)
- Antineoplastic Agents, Immunological
(administration & dosage)
- B7-H1 Antigen
(genetics, immunology)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, genetics, immunology, pathology)
- Drug Therapy, Combination
- Female
- Humans
- Immune Checkpoint Inhibitors
(administration & dosage)
- Immunotherapy
- Lung Neoplasms
(drug therapy, genetics, immunology, pathology)
- Male
- Middle Aged
- Retrospective Studies
- Treatment Outcome
|